^

Health

Galawit

, medical expert
Last reviewed: 09.08.2022
Fact-checked
х

All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.

We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.

If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.

The drug Galavit (analogue - Tamerite) belongs to the group of pharmacological agents intended to stimulate immunity. By activating the protective forces of the body Galavit has an anti-inflammatory effect, contributing to a decrease in the intensity of inflammatory processes and the elimination of their symptoms.

Indications Galawit

As a means of directed immunocorrection, Galavit is used in the complex treatment of such diseases as:

Indications for the use of Galavit is also secondary immune deficiency, for example, after radiation therapy of certain oncological diseases.

trusted-source[1]

Release form

The preparation Galavit is available in three forms: tablets (25 mg each) for resorption under the tongue, powder for the preparation of the injection solution (100 mg in one bottle) and rectal suppository (0.1 g of the drug in one suppository).

trusted-source[2], [3]

Pharmacodynamics

The therapeutic effect of Galavit is due to the fact that the synthetic low-molecular substance aminodihydrophthalazinedione sodium (5-amino-1,2,3,4-tetrahydrophthalazine-1,4-dione sodium salt) normalizes the functional activity and metabolism of mononuclear blood phagocytes (macrophages) ).

On the one hand, for some time (no more than 6 hours), the enhanced synthesis by macrophages of various anti-inflammatory cytokines (specific proteins of the cells of the immune system) is slowed down, as a result of which intoxication and the degree of inflammatory reactions of the organism caused by pathogenic microorganisms decrease.

On the other hand, with weakened immunity, the microbiostatic function of neutrophilic leukocytes is activated: the process of capture and destruction of foreign cells (phagocytosis) is enhanced, and the synthesis of interferons and protective antibodies is accelerated. As a result, the ability to withstand various infections (nonspecific resistance of the body) is significantly increased.

trusted-source[4]

Pharmacokinetics

Getting into the body, the drug Galavit is not subjected to any chemical changes and is excreted by the kidneys with urine. The duration of the therapeutic effect of the drug after its single administration is an average of three days.

When using tablets, the half-life of Galavite is about 30 minutes; when injecting those injections - 15-30 minutes, after applying rectal suppositories - 60-70 minutes.

trusted-source[5]

Dosing and administration

The dosage and duration of the course of Galavit therapy are determined by the doctor prescribing the drug and depend on the etiology, pathogenesis and clinical manifestations of the particular disease, as well as on the patient's condition.

Tablets for resorption under the tongue are prescribed one tablet 4 times a day or two tablets - twice a day.

To prepare a solution for injection Galavit in powder form is dissolved in water for injection or 0.9% sodium chloride (2 ml). The drug is injected into the muscle. The usual dose for infectious diseases (in the acute period) is 200 mg. Then the dosage is corrected and can be reduced to the complete disappearance of signs of intoxication. The maximum number of injections per treatment course is no more than 25.

In the treatment of chronic inflammation against a background of reduced immunity, the regimen of Galavit is 100 mg once every three days or 100 mg once a day for 5 days, after which injections (100 mg each) are done once every 2-3 days. The course of therapy - no more than 20 injections.

Galavite in the form of suppositories is usually prescribed for 2 rectal suppositories once, then for 1 suppository 2 times a day until the symptoms of inflammation disappear. Then the dose is reduced to one suppository once every three days. The total dose of the full course of treatment is no more than 25 suppositories.

trusted-source[7], [8], [9], [10]

Use Galawit during pregnancy

The use of Galavit during pregnancy, as well as during breastfeeding is contraindicated.

Contraindications

Contraindication to the use of this drug is an individual hypersensitivity to the substances that make up its composition.

Side effects Galawit

There are no reports of the development of any undesirable side effects arising from the treatment with Galavit. But the likelihood of an individual allergic reaction when using the drug exists.

trusted-source[6]

Overdose

There are no reports of an overdose of this medication (in all three forms).

Storage conditions

The drug Galavit in the form of suppositories must be stored at a temperature of + 5-12 ° C - in a dry place, protected from light. Optimal storage temperature the preparation in the form of a powder for the preparation of a solution is + 15-25 ° C.

trusted-source[11], [12], [13], [14]

Shelf life

Shelf life of the drug in the form of tablets and in the form of suppositories is 2 years, in the form of powder (for the preparation of solution for injection) - 4 years.

trusted-source[15], [16]

Attention!

To simplify the perception of information, this instruction for use of the drug "Galawit" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.

Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.

Translation Disclaimer: For the convenience of users of the iLive portal this article has been translated into the current language, but has not yet been verified by a native speaker who has the necessary qualifications for this. In this regard, we warn you that the translation of this article may be incorrect, may contain lexical, syntactic and grammatical errors.

You are reporting a typo in the following text:
Simply click the "Send typo report" button to complete the report. You can also include a comment.